Skip to main content
. Author manuscript; available in PMC: 2023 Feb 9.
Published in final edited form as: Gynecol Oncol. 2022 Jul 5;166(3):425–431. doi: 10.1016/j.ygyno.2022.06.017

Fig. 2.

Fig. 2.

Best overall response by cohort (efficacy analysis set).

BRCAm, BRCA1 and/or BRCA2 mutation; CI, confidence interval; CR, complete response; DCR, disease control rate; gBRCAm, germline BRCA mutation; HRD, homologous recombination deficiency; NE, not evaluable; ORR, objective response rate; PD, progressive disease; PR, partial response; sBRCAm, somatic BRCAm; SD, stable disease.